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REGULAR ARTICLE

Blood–brain barrier permeability in survivors of immune-mediated
thrombotic thrombocytopenic purpura: a pilot study
Shih-Han Susan Huang,1-3* Katerina Pavenski,4 Ting-Yim Lee,2,3,5 Michael T. Jurkiewicz,5 Aditya Bharatha,6 Jonathan Dale Thiessen,2,3,5
berge,2,3,5 Jennifer Mandzia,7 David Barth,8 Christoph Licht,9 and Christopher Jordan Patriquin8
Keith St. Lawrence,2,3 Jean The

Key Points


Patients with iTTP in
remission had
pathologically
increased blood–brain
barrier permeability,
which improved but
did not resolve 6
months later.

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening
disorder of systemic microthrombosis and organ ischemia. The etiology of chronic cerebrovascular outcomes in iTTP survivors is largely unknown. In this pilot study, we measured blood–brain barrier (BBB) permeability in patients with iTTP at the start of remission
and 6 months later. This prospective pilot study included 7 adult patients with incident
iTTP. Eligibility criteria included ADAMTS13 activity , 10% and detectable inhibitor at
diagnosis. Patients were recruited from London Health Sciences Centre in Canada (20172019) within 3 days of hospital admission and followed for 6 months after remission
(deﬁned as normalization of platelet count and lactate dehydrogenase with no clinical signs
or symptoms of microvascular injury for more than 30 days after the last plasma exchange).
All patients had cerebral computed tomography perfusion scans with BBB permeability
surface product measurements. Patients (5 women, 2 men) had a mean age of 48 years
(range, 21-77 years). At diagnosis, patients had a mean platelet count of 22 (standard
deviation [SD], 25) 3 109/L. At the start of remission, mean BBB permeability surface
product was 0.91 (0.30) mL/min/100 g. Six months later, the mean permeability surface
product was 0.56 (0.22) mL/min/100 g, with a mean difference of 20.312 mL/min/100 g (95%
conﬁdence interval: 20.4729 to 20.1510; P 5 .0032). In this pilot study of patients with iTTP,
pathologically increased BBB permeability was evident, and although there was some
improvement, this persisted 6 months after remission. Future work will explore the chronicity of these ﬁndings and their clinical implications.

Introduction
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening blood disorder
caused by antibody-mediated inhibition of the proteolytic enzyme ADAMTS13 (A Disintegrin And Metalloproteinase with a Thrombospondin type 1 motif, member 13). Severe deﬁciency of ADAMTS13 activity
leads to accumulated ultra-large von Willebrand factor multimers, increased platelet aggregation, and subsequent microvascular thrombosis within many organs.1-5 Therapeutic plasma exchange (TPE), with or without corticosteroids and/or other immunosuppressive therapies, has been shown to signiﬁcantly reduce the
30-day mortality rate from 90% to 20%.6-13
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Although some studies have also used magnetic resonance imaging
(MRI) technology to assess BBB integrity, it cannot quantify the
degree of permeability. The computed tomography (CT) perfusion
technique for the brain used in our pilot study was developed (by
coauthor T.-Y.L.) to quantitatively assess brain perfusion and BBB
integrity, where the mean permeability surface (PS) product of the
brain (measured in mL/min/100 g) was determined.18-20 Higher PS
product scores indicate greater permeability (ie, worse BBB leakage).
Using this CT perfusion technique to assess 12 sequential stroke
patients, it was found that their mean BBB PS products were 2.24
6 1.61 mL/min/100 g on the ischemic side of the brain and 1.59
6 0.67 mL/min/100 g on the contralateral region at the time of stroke
(unpublished data). We used these novel 256-slice CT perfusion
scans to assess the gross structural pathology and cerebral vascular
system, including measuring the permeability of the BBB. Cerebral
blood ﬂow, cerebral blood volume, and mean transit time were also
measured, which could be potentially affected by microvascular
thrombosis.
In this prospective observational pilot study, we sought to assess for
structural and ischemic injuries in iTTP who had achieved remission
and characterize their BBB integrity using novel imaging techniques.
We hypothesize that patients with iTTP have long-term risk of depression and neurocognitive changes. We hypothesize that patients with
iTTP may have persistent increased BBB permeability after their acute
episode despite hematologic remission. Understanding and monitoring neurocognitive function is particularly relevant in this young patient
population with a median age of 40 years at the time of their ﬁrst iTTP
episode,21 although effective strategies for this remain unclear. Characterizing the pathophysiology and progression of cerebrovascular
injury in iTTP may help to improve the long-term care and prognosis
of our patients with iTTP and guide future targeted therapies to halt
or even reverse the damage.

Materials and methods
Study design and setting
We conducted a prospective observational pilot study of patients with
iTTP. Patients were enrolled between 1 January 2018 and 1 March
2019 at the London Health Sciences Centre (London, ON, Canada).
Patients were approached by a research coordinator at the time of
hospital admission and diagnosis. All patients in this study provided
written informed consent (all consents were obtained before hospital
discharge). The study received ethics approval from Western University’s Health Sciences Research Ethics Board (HSREB# 108273).
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Eligibility criteria
Patients were eligible if they were age $ 18 years and had a new diagnosis of iTTP, deﬁned as (1) platelet count , 150 3 109/L; (2) microangiopathic hemolytic anemia (presence of schistocytes on peripheral
blood ﬁlm); (3) LDH . 1.25 3 the upper limit of normal; (4)
ADAMTS13 activity , 10%; and (5) positive anti-ADAMTS13 inhibitor. Diagnosis required all 5 criteria be met. Patients were excluded if
they had a prior diagnosis of iTTP, if they had an alternative diagnosis
of thrombotic microangiopathy (eg, hemolytic uremic syndrome, disseminated intravascular coagulopathy, or malignant hypertension), or
if they had iTTP secondary to drugs or connective tissue disease.
Patients with a history of any of the following conditions were also
excluded: hypertension, diabetes mellitus, cardiovascular disease,
cerebrovascular disease, vasculitis of central nervous system, or a history of contrast allergies, severe asthma, and/or advanced kidney dysfunction (glomerular ﬁltration rate , 30 mL/min/1.75 m2).

Data collection
Clinical characteristics during the acute iTTP phase were obtained
from medical charts as follows: ADAMTS13 activity (enzyme-linked
immunosorbent assay; reference range, 41%-130% [Technozym,
Vienna, Austria]), complete blood counts, creatinine, peripheral blood
ﬁlm (as reported by hematologist), LDH, and the TPE regimen. Information on other treatments received was also recorded (eg, corticosteroids, rituximab, cyclophosphamide, cyclosporine, vincristine,
bortezomib, and splenectomy). Data were collected within 1 month
of remission from iTTP and again 6 months later. Remission was
deﬁned as platelet count . 150 3 109/L, LDH , 23 the upper limit
of normal (5214 U/L), and no clinical evidence of iTTP for at least 30
days since the last TPE.22

Imaging protocol
Cerebral CT perfusion scans were done within 1 month of remission
from TTP and again 6 months later. The CT protocol for the brain was
developed by a collaborator (T.-Y.L.) to quantitatively assess brain perfusion and BBB integrity, reported as the PS product [ml/min/
100g].18-20 Images were acquired on the 256-slice GE Healthcare
Revolution CT scanner (Waukesha, WI) using the following protocol:
5-second delay from the start of intravenous contrast injection (370
mg/mL iodine) at a dosage of 0.7 mL/kg body weight and at an injection rate of 3 mL/s; 19 scans at 2.5-second intervals, followed by 7
scans at 15-second intervals using 80 kV, 45 mAs, and 16 slices of
5-mm thickness for each scan. The total scan time was 150 seconds.
We have shown previously that a shorter scan time would lead to inaccuracy (.10%) in the measurement of BBB PS product.23 Images
were reconstructed with an iterative algorithm (ASIRv, GE Healthcare)
to reduce CT noise from the low radiation dose used. The radiation
dose was estimated to be 69.0 mGy for CTDIvol and 552.7 mGycm
for dose length product. The estimated effective radiation dose was
1.2 mSv (the annual background radiation dose is approximately 3
mSV, which is lower than that of a conventional CT scan [4 mSV]).

Imaging analysis
From the cerebral CT perfusion images, localization images of the
head were read by the study radiologist (M.T.J.) to assess for any
gross pathology. One operator (F.S.) used prototype software developed in T.-Y.L.’s laboratory (CTP5; GE Healthcare) to calculate parametric maps of cerebral blood ﬂow, cerebral blood volume, mean
transit time, and PS product from the ﬁrst- and second-phase CT
26 OCTOBER 2021 • VOLUME 5, NUMBER 20
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The current standard of care for patients with iTTP focuses primarily
on the normalization of hematologic parameters (ie, platelets, lactate
dehydrogenase [LDH]); however, patients who survive the initial
iTTP episode may be at increased risk for long-term cerebrovascular
dysfunction, cognitive impairment, and depression.14,15 The 8-year
mortality rate is 33%, and a signiﬁcant proportion of deaths is attributed to cerebrovascular disease.14 The pathologic mechanism of
these complications in iTTP is unclear. However, blood–brain barrier
(BBB) disruption and damage have been linked to the development
of depression and early dementia,16,17 and its relationship to
ADAMTS13 deﬁciency in the context of stroke models has also
recently been published. Therefore, we elected to assess this specifically in our patients with iTTP.

Statistical analysis
Means and standard deviations (SD) are reported for normally distributed data and medians and interquartile ranges (25th, 75th percentiles) for nonnormally distributed data. Patient and clinical
characteristics are summarized at the time of diagnosis and at the start
of remission. The mean PS products over the left and right cerebral
hemispheres are reported at the start of remission and 6 months later.
Mean differences between measurements taken at these 2 time points
(ie, time 1 minus time 2) are reported with 95% conﬁdence intervals
(CIs). We also report mean cerebral blood ﬂow, cerebral blood volume, and mean transit time, stratiﬁed by age and ADAMTS13 activity.
For normally distributed data, a 1-sample t test was used to test
whether the mean change in outcomes was signiﬁcantly different
from zero. All analyses were conducted using SAS software version
(9.4).

Results
Of 12 patients approached to participate in the study, 1 patient did
not consent, and a second was diagnosed with lupus-related secondary iTTP and therefore excluded from the pilot. Of the 10 patients who
agreed to participate (7 women and 3 men), 7 had a cerebral CT perfusion scan done within 30 days of remission and again at 6 months.
Three of the 10 patients had the ﬁrst CT scan but not the second
scan, which was cancelled because of the COVID-19
pandemic–related institutional restrictions. The ﬁnal analyzable sample
therefore included 7 patients with complete data.
Patient characteristics at the time of hospital admission are shown in
Table 1. At the time of diagnosis, patients were between 21 and 77
years of age (mean, 48 years). Mean laboratory values included a
platelet count of 22 (SD, 25) 3 109/L, hemoglobin of 84 (SD, 18)
g/L, and LDH of 1465 (SD, 813) U/L. All patients had ADAMTS13
activity , 1% with detectable anti-ADAMTS13 antibodies. TPE was
started on the ﬁrst day of diagnosis, and all patients received prednisone; 6 of the 7 also received rituximab for refractory disease. Two
patients received vincristine, again for refractory disease, and 1 patient
received a placebo drug as part of a separate clinical trial. At the time
of the ﬁrst scan (Table 1), patients had a mean platelet count of 251
(SD, 41) 3 109/L, hemoglobin of 126 (SD, 13) g/L, and LDH of 254
(SD, 114) U/L. The median ADAMTS13 activity was 81% (19%,
91%), although it ranged from ,1% to 96%. Of note, all patients
maintained their remission status throughout the study period.
26 OCTOBER 2021 • VOLUME 5, NUMBER 20

Average map
The average map is the average of all source images of a CT perfusion
study. It provides a high signal-to-noise, contrast-enhanced image of
the head that accentuates the contrast between gray and white matter. All patients had normal average map images except for a 77-yearold man who had chronic ischemic changes with some volume loss
reported.

Cerebral CT perfusion studies of the head
On the initial scans (ie, at remission), the mean whole brain mean PS
product was 0.91 6 0.30 mL/min/100 g, with 0.92 6 0.32 mL/min/
100 g on the right side and 0.89 6 0.29 mL/min/100 g on the left
(Table 2). The whole brain mean PS product at 6 months was 0.59
6 0.22 mL/min/100 g, and the mean change from the ﬁrst study to
the second was 20.311 mL/min/100 g (95% CI: 20.4729 to
20.1510 mL/min/100 g; P 5 .0032). Cerebral blood ﬂow, cerebral
blood volume, and mean transit time did not show signiﬁcant changes
between initial and 6-month scans. Figure 1 shows the average cerebral blood ﬂow, cerebral blood volume, mean transit time, and PS
product map (5.0-mm slice) of 1 patient at the start of remission
and 6 months later. Figure 2 shows the PS product map of all 7
patients at both time points. The PS product in patients who normalized their ADAMTS13 activity in remission had signiﬁcant improvement at 6 months. Those with ADAMTS13 activity , 40% at the
time of remission did not demonstrate a signiﬁcant difference (supplemental Table 1). However, there were only 2 patients in this subgroup.

Discussion
Chronic neurocognitive changes in survivors of iTTP have been recognized for years, although the pathophysiology has remained unclear. In
this pilot study of adult patients with iTTP in remission, we found that
most do not have any gross pathologic changes. Previous work has
shown that most patients will have normal conventional head CT imaging, even during acute episodes.26 Although CT studies can be normal in iTTP patients, Alwan et al27 demonstrated that hyperintense
lesions can be identiﬁed on their MRI, which was associated with
worse cognitive impairment. Hamilton et al28 also described similar
hyperintense lesions in patients who have recovered from iTTP episodes. Further studies to assess the correlation between BBB permeability, MRI white matter changes, and neurocognitive impacts would
be important.
Compared with conventional imaging, cerebral CT perfusion scans
allow quantiﬁcation of the PS product, an objective measurement
for monitoring BBB disruption. In our study, the mean whole brain
PS product was 0.91 6 0.30 and 0.59 6 0.22 mL/min/100 g at
remission and 6 months later, respectively, with a mean change (ie,
improvement) of 20.311 mL/min/100 g (95% CI: 20.4729 to
20.1510 mL/min/100 g; P 5 .0032). Although improvement was
observed over this time, BBB permeability was still detected at 6
months. After acute stroke, BBB permeability typically peaks after 7
days and starts to improve afterward.29
Disruption of the BBB has been studied in other diseases. In multiple
sclerosis, there are data suggesting dysregulation of the BBB and
transendothelial migration of activated leukocytes are early signs of
disease.30 The mechanism for BBB disruption in multiple sclerosis
is not completely understood but may be driven by cytokine- and
chemokine-mediated
injury.31
Furthermore,
a
study
of
NEUROVASCULAR IMPACT OF TTP
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perfusion data. Arterial input and venous time-density curves (TDCs)
were derived from an internal carotid artery in the cavernous sinus
and the posterior superior sagittal sinus, respectively. To avoid operator bias, 2 collaborators (M.T.J. and F.S.) were blinded from patients’
clinical data. We corrected partial volume averaging of the arterial
input TDCs by scaling the curve with the ratio of the area under the
venous TDCs to the area under the arterial input TDCs. Maps were
calculated by deconvolving the arterial input TDCs from the brain tissue TDCs from 3 3 3 pixel blocks of CT source images with use of
the Johnson-Wilson-Lee model to estimate cerebral blood ﬂow, cerebral blood volume, mean transit time, and PS product.24 BBB permeability should be close to zero, and a recent study has shown that its
standard deviation is 0.24 mL/min/100 g.25 For quantitative assessment, the parametric maps were analyzed by the same operator
(F.S.) using custom software (Interactive Display Language v6.1;
Research Systems, Boulder, CO).

Table 1. Clinical characteristics of iTTP patients at baseline, within 30 days of remission (month 0) and 6 months after remission (month 6)
Baseline

Month 0

Month 6

Demographic characteristics (N 5 7)*
Women, n (%)

5 (71%)

Age at symptom onset, y
Mean (SD)

48 (19)

Median (25th, 75th percentiles)

50 (30, 59)

Range

21-77

Body mass index, kg/m2
36 (8)

Median (25th, 75th percentiles)

33 (33, 41)

Range

25-48

Clinical characteristics
Platelet count*, 3 109/L†
Mean (SD)

22 (25)

251 (41)

239 (44)

Median (25th, 75th percentiles)

11 (10, 26)

248 (229, 290)

239 (223, 261)

,10-76

183-299

161-306

Range
Hemoglobin, g/L
Mean (SD)

84 (18)

126 (13)

128 (17)

Median (25th, 75th percentiles)

79 (78, 102)

126 (122, 141)

121 (116, 149)

53-106

102, 142

109 – 153

Range
Lactate dehydrogenase, U/L (upper limit
of normal, 214 U/L)
Mean (SD)

1465 (813)

254 (114)

217 (83)

Median (25th, 75th percentiles)

1420 (671, 2256)

249 (161, 339)

197 (143, 263)

417-2500

79, 413

134-371

Range
ADAMTS13,† %
Mean (SD)

,1‡

61 (41)§

75 (40)§

Median (25th, 75th percentiles)

,1

81 (19, 91)

89 (52, 114)

Range

,1

,1, 96

,1-.114

Serum creatinine, mmol/L
Mean (SD)

123 (40)

Median (25th, 75th percentiles)

122 (95, 157)

73 (66, 107)

71 (64, 76)

65-186

58, 220

62-115

Range
Missing, n (%)

0 (0%)

100 (56)

75 (18)

0 (0%)

Immunosuppressive therapy
Prednisone, n (%)

7 (100%)

Rituximab, n (%)

6 (86%)

Vincristinejj

2 (29%)

*There are no missing values for these demographic and clinical characteristics.
†Platelet count , 10 3 109/L (our laboratory does not quantify , 10 3 109/L); a value of 5 3 109/L was given for this summary.
‡All patients had ADAMTS13 levels , 10% and inhibitor levels . 14 U/mL. All patients had detectable inhibitor level.
§A value of ,1% was replaced with a value of 1 for this summary; a value of .114 was replaced with 114 for this summary. Inhibitors were not run because most patients had normalized
their ADAMTS13 activity.
jjUsed in cases of refractory iTTP not responsive to TPE and corticosteroids alone.

thrombocytopenia in patients with HIV suggested that platelets may
have a “protagonist” role in BBB disruption.32 This may suggest additional mechanisms to BBB disruption in patients with iTTP. Although
permeability measurement is not affected by renal dysfunction, the
impact of therapeutic plasma exchange, corticosteroids, and other
immunosuppressive treatments on BBB disruption/repair is not
known. In a future larger study, treatment inﬂuence on BBB

4214
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permeability will be evaluated, and long-term data will be collected
to more fully assess BBB permeability chronically in this population.
Normal cerebral blood ﬂow, cerebral blood volume, and mean transit
time are 44.4 6 6.5 mL/100 g, 3.8 6 0.7 mL/100 g, and 3.2 to 4.4
seconds.33,34 Although we expected these parameters to be compromised in our patients, as seen in stroke or anemia, these values were

26 OCTOBER 2021 • VOLUME 5, NUMBER 20
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Mean (SD)

Table 2. BBB permeability surface product, cerebral blood ﬂow, cerebral volume, and mean transit time measurements at the time of
remission (month 0) and 6 months later (month 6)
Month 0 (N 5 7)

Month 6 (N 5 7)

Mean change(95% CI)

P*

0.92 (0.32)

0.61 (0.22)

20.3075 (20.4428, 20.1722)

.0014

PS (ml/min/100 g), weighted average (mean [SD])
Right side
Left side

0.89 (0.29)

0.58 (0.23)

20.3138 (20.5122, 20.1155)

.0083

Overall†

0.91 (0.30)

0.59 (0.22)

20.3119 (20.4729, 20.1510)

.0032

Right side

46.8 (4.7)

43.2 (2.8)

23.5709 (28.9584, 1.8165)

.1560

Left side

47.8 (5.8)

43.3 (4.9)

24.5457 (29.5221, 0.4307)

.0668

Overall†

48.2 (3.9)

44.1 (4.0)

24.0461 (29.0938, 1.0015)

.0975

Right side

2.84 (0.30)

2.61 (0.24)

20.2313 (20.5939, 0.1314)

.1696

Left side

2.91 (0.32)

2.60 (0.38)

20.3041 (20.6141, 0.0060)

.0533

Overall†

2.93 (0.25)

2.66 (0.32)

20.2699 (20.5957, 0.0559)

.0890

CBF (ml/100 g), weighted average (mean [SD])

MTT (s), weighted average (mean [SD])
Right side

3.65 (0.12)

3.62 (0.13)

20.0275 (0.1801, 0.1250)

.6743

Left side

3.66 (0.11)

3.60 (0.14)

20.0610 (20.2210, 0.0989)

.3865

Overall†

3.73 (0.25)

3.68 (0.19)

20.0488 (20.2086, 0.1110)

.4833

Results are presented as mean (standard deviation). There are no missing values. CBF, cerebral blood ﬂow; CBV, cerebral blood volume; MTT, mean transit time.
*A one-sample t test was used to test whether the mean change in each outcome was signiﬁcantly different from zero.
†The overall value is calculated as the weighted average of both the right and left sides.

still within the normal range.35 This may be because we assessed
these parameters during their remission period. We will need to further study these factors along with along with BBB permeability during acute iTTP episodes for a complete comparison.
Reproducibility of BBB PS measurements, using the same theoretical
basis in another disease area (liver tumor), has been reported to be
6.7% to 12.1% in both animal and human subjects.36,37 Contrastenhanced MRIs of BBB PS product have relied mainly on subjective
assessment of image intensity at the site of compromised BBB. Our
CT perfusion technique, with objective measurement of BBB PS
product in units of mL/min/100 g, has a physiologic basis, and the
absolute PS values would facilitate an objective and more sensitive
detection of changes in longitudinal studies.38 BBB PS as a marker
of disruption has been implicated in the development of cognitive dysfunction in a recent study by Nation et al.17 Of note, the method of
BBB PS measurement in this publication was the same CT-based
method used in our pilot study and can serve both as clinical validation
of our BBB PS measurement methodology and proving the association of abnormal PS product with development of insidious cognitive
dysfunction outside of stroke.
The standard use of TPE and immunosuppression has led to signiﬁcant improvements in survival for patients with iTTP; however, longterm complications persist even in those in remission.14 Most signiﬁcantly, mood disorders, neurocognitive changes, and strokes are
reported at much greater rates than in the general population, despite
recovery of ADAMTS13 activity.39,40 The observation of persistent
BBB leakage after the initial iTTP diagnosis contrasts with ﬁndings
in ischemic stroke patients (supplemental Figure 1) and allows us to
further explore the correlation between BBB leakage in iTTP and its
long-term neuropsychiatric complications in a future study.41 It is
unclear why patients with iTTP who are in hematologic remission still
have elevated BBB PS products. Although we did not measure this in
26 OCTOBER 2021 • VOLUME 5, NUMBER 20

our study, Ferrari et al42 have shown that patients with iTTP may have
persistent circulating ADAMST13 immune complexes. Also, serum
S100b, primarily synthesized by astrocytes, is quickly released into
the circulation when the BBB is disrupted.43 These and additional biomarkers to assess BBB permeability could be considered in future
studies in iTTP.
Management of acute iTTP episodes includes TPE and immunosuppression with corticosteroids and other medications. Steroids may
have some potential beneﬁt in reducing inﬂammation and slowing
down BBB leakage, although the extent of this effect is currently
unknown. Other therapies such as caplacizumab and recombinant
ADAMTS13 are potential new treatments for iTTP.44 Acutely, they
may reduce the microthrombotic burden and thereby reduce BBB
damage. Further assessment of the impact of these therapies on
BBB leakage will be important for future studies.
This pilot study does have some limitations. First, it is possible that
our ﬁndings could be explained by the coexistence of other conditions or comorbidities; however, to minimize such confounding, we
excluded patients with secondary iTTP and other thrombotic microangiopathies. In addition, the radiologist who reported these
images was blinded from the clinical data. None of the patients
had known cerebrovascular conditions before their initial iTTP diagnosis. In addition, all patients were recruited at the time of their ﬁrst
presentation, thereby eliminating the potential of residual effects
from prior episodes. Second, although our study did not include
neurocognitive assessments, other studies have shown that many
patients with iTTP demonstrate adverse neurocognitive effects for
months and even years after their initial iTTP episode.14 Finally,
we do not have healthy control imaging data because of the risk
of radiation. However, as shown, the BBB PS values of 12 sequential stroke patients were higher on the ischemic side of the brain
(2.24 6 1.61 mL/min/100 g), which suggests that our patients
NEUROVASCULAR IMPACT OF TTP
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CBV (ml/100 g), weighted average (mean [SD])

Cerebral
blood flow

Cerebral
blood volume

Mean
transit time

Permeability
surface product

Figure 1. Representative cerebral CT perfusion imaging of a patient. Representative imaging slices of the cerebral CT perfusion scans of a patient. Images include
the localization images, cerebral blood ﬂow slices, cerebral blood volume slices, minute transit time images, and PS product images at the time of remission and 6 months later.
Of note, images of a normal brain would have minimal contrast leakage through the BBB (ie, minimal blue color). The red arrow indicates diffuse BBB leakage at month 0
(1.26 ml/min/100 g) with modest improvement at month 6 (0.96 ml/min/100 g), shown with yellow arrow. Please see supplemental Figure 1 for comparison of PS product
images of diffuse BBB leakage in a patient with TTP, localized BBB leakage in a stroke patient, and minimal BBB leakage in another stroke patient.

may have had much higher BBB values during their acute episodes.
We plan to conduct a larger study to further examine whether the
degree and duration of BBB permeability and associated consequences (eg, white matter injury) correlates with depression and
overall neurocognitive function. During this study, we will also capture the BBB permeability data during the acute iTTP episodes.

neurocognitive outcomes, anatomical changes, and the degree
and duration of increased BBB leakage requires ongoing evaluation, as do strategies to mitigate these consequences. We
focused on neurologic outcomes, but because iTTP is a systemic
disease, other areas of microvascular damage may also go unnoticed. New therapeutic options, including caplacizumab and
recombinant ADAMTS13, may have such a role, but this is yet to
be proven. Long-term implications of these ﬁndings will be examined in future research.

In conclusion, our pilot study provides preliminary evidence that
pathologic BBB permeability is elevated in survivors of iTTP up
to 6 months after hematologic remission. The relationship between

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Patient 7

Month 0

Patient 1

176 × 109 /L

299 × 109 /L

231 × 109 /L

183 × 109 /L

248 × 109 /L

290 × 109 /L

229 × 109 /L

ADAMTS13

19%

74%

>94%

91%

<1%

87%

67%

BBB PS

1.26 mL/min/100g 1.04 mL/min/100g 1.06 mL/min/100g 0.62 mL/min/100g 0.65 mL/min/100g 0.88 mL/min/100g 0.46 mL/min/100g

Month 6

Platelet

Platelet

232 × 109 /L

253 × 109 /L

223 × 109 /L

161 × 109 /L

239 × 109 /L

306 × 109 /L

261 × 109 /L

ADAMTS13

52%

>94%

>94%

61%

<1%

>94%

89%

BBB PS

0.67 mL/min/100g 0.78 mL/min/100g 0.80 mL/min/100g 0.53 mL/min/100g 0.33 mL/min/100g 0.50 mL/min/100g 0.33 mL/min/100g

Figure 2. BBB PS map of all 7 patients at months 0 and 6. The yellow circle represents highest BBB PS product region in the 7 patients with iTTP (1.80 ml/min/100 g,
at right parietal lobe). There is intense blue color in that region. For the same patient, the red and blue arrows represent a signiﬁcant change between month 0 and 6 PS
products (1.72-0.73 ml/min/100 g at the left frontal lobe). Please see supplemental Figure 1 for comparison of PS product images. Patient 4 had chronic ischemic changes
on the CT images. Patient 5 had persistent low ADAMTS13 activities , 1% with inhibitor level . 94 U/mL, consistent with iTTP.
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